Multiple Sclerosis Clinical Trials Near Me
As of October 12, 2026, 525 Multiple Sclerosis clinical trials are recruiting or about to open (368 recruiting now, 157 opening soon). 152 of them have at least 1 open site in the United States, across 41 states. Enter your ZIP code to see which are closest to you.
Also on Trial Friend:Multiple Sclerosis pageMatch Me
All 368 Multiple Sclerosis trials and their US sites
Enter your ZIP code above to sort them by how far their nearest open site is from you.
- A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)TG Therapeutics Investigational Trial Site, Birmingham, Alabama; TG Therapeutics Investigational Trial Site, Cullman, Alabama; TG Therapeutics Investigational Trial Site, Huntsville, Alabama and 106 more sitesRecruitingAges 18+Run by TG Therapeutics, Inc.
- Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.Perseverance Research Center, Scottsdale, Arizona; University of California Irvine, Irvine, California; Medstar Washington Hospital Center, Washington D.C., District of Columbia and 40 more sitesRecruitingPhase 3Ages 40 to 70Run by Novartis Pharmaceuticals
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOUniversity of California Davis Comprehensive Cancer Center, Sacramento, California; Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut; Yale University, New Haven, Connecticut and 37 more sitesRecruitingPhase 1Ages 18+Run by National Cancer Institute (NCI)
- Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of UblituximabTG Therapeutics Investigational Trial Site, Birmingham, Alabama; TG Therapeutics Investigational Trial Site, Cullman, Alabama; TG Therapeutics Investigational Trial Site, Orange, California and 36 more sitesRecruitingPhase 3Ages 18 to 65Run by TG Therapeutics, Inc.
- A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple SclerosisAlabama Neurology Associates PC, Birmingham, Alabama; Ctr for Neurology and Spine, Phoenix, Arizona; AZ Integrated Neuro and Spine, Phoenix, Arizona and 31 more sitesRecruitingPhase 3Ages 18 to 65Run by Novartis Pharmaceuticals
- A Study of Orelabrutinib in Patients With Secondary Progressive Multiple SclerosisArizona Neuroscience Research, LLC, Phoenix, Arizona; Perseverance Research Center, LLC (PRC), Scottsdale, Arizona; Fullerton Neurology and Headache Center, Fullerton, California and 22 more sitesRecruitingPhase 3Ages 18 to 60Run by Zenas BioPharma (USA), LLC
- Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple SclerosisNorth Central Neurology Associates- Site Number : 8401100, Cullman, Alabama; Alabama Neurology Associates- Site Number : 8400115, Homewood, Alabama; Center for Neurology and Spine - Phoenix - East Bell Road- Site Number : 8400195, Phoenix, Arizona and 20 more sitesRecruitingPhase 3Ages 18 to 60Run by Sanofi
- Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)Stanford Multiple Sclerosis Center, Palo Alto, California; Rocky Mountain Multiple Sclerosis Center, University of Colorado School of Medicine, Aurora, Colorado; Northwestern University, Evanston, Illinois and 17 more sitesRecruitingPhase 3Ages 18 to 55Run by National Institute of Allergy and Infectious Diseases (NIAID)
- A Study of Orelabrutinib in Patients With Primary Progressive Multiple SclerosisPerseverance Research Center, Scottsdale, Arizona; Regina Berkovich MD, PhD Inc., West Hollywood, California; Nova Clinical Research, LLC, Bradenton, Florida and 14 more sitesRecruitingPhase 3Ages 18 to 60Run by Zenas BioPharma (USA), LLC
- A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis SpasticityAlabama Neurology Associates, Birmingham, Alabama; Perseverance Research Center,LLC, Scottsdale, Arizona; Aqualane Clinical Research, Naples, Florida and 11 more sitesRecruitingPhase 2Ages 18 to 70Run by Celgene
- Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple SclerosisUniversity of California Davis Health, Sacramento, California; University of South Florida, Tampa, Florida; University of Chicago Medical Center, Chicago, Illinois and 6 more sitesRecruitingPhase 3Ages 10 to 17Run by Bristol-Myers Squibb
- The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot StudyUniversity of California Irvine Center for Clinical Research, Irvine, California; Shepherd Center, Atlanta, Georgia; Johns Hopkins School of Medicine, Baltimore, Maryland and 6 more sitesRecruitingAges 22 to 60Run by SetPoint Medical Corporation
- An Open-label Study of AZD0120 in Adults With Multiple Sclerosis8 open sitesRecruitingPhase 1Ages 18 to 60Run by AstraZeneca
- Treatment of Participants With Primary or Secondary Progressive Multiple SclerosisUC San Diego, La Jolla, California; University of Kansas Medical Center, Kansas City, Kansas; Mayo Clinic, Rochester, Minnesota and 5 more sitesRecruitingPhase 1/2Ages 18 to 65Run by Tr1X, Inc.
- A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 YearsQuest Research Institute, Farmington Hills, Michigan; Washington University School of Medicine Neurology Clinical Unit, St Louis, Missouri; Oklahoma Medical Research Foundation (OMRF) MS Center of Excellence, Oklahoma City, Oklahoma and 3 more sitesRecruitingPhase 2Ages 18 to 55Run by ModernaTX, Inc.
- Care in Multiple Sclerosis (MS)University of Alabama at Birmingham, Birmingham, Alabama; University of California, San Francisco, San Francisco, California; University of Colorado Denver, Aurora, Colorado and 3 more sitesRecruitingAges 18+Run by NYU Langone Health
- A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic DiseasesHoag Memorial Hospital Presbyterian, Newport Beach, California; Stanford Neuroscience Health Center, Palo Alto, California; Columbia University Irving Medical Center, New York, New York and 2 more sitesRecruitingPhase 1Ages 18 to 75Run by Kite, A Gilead Company
- A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 TherapyClinical Endpoints, LLC, Scottsdale, Arizona; Neurology Associates, PA, Maitland, Florida; Atlanta Neuroscience Institute, Atlanta, Georgia and 1 more siteRecruitingPhase 4Ages 18 to 65Run by Genentech, Inc.
- A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)3 open sitesRecruitingPhase 2Ages 18 to 70Run by Sundance Biosciences, Inc.
- Central Vein Sign in Multiple Sclerosis Extension StudyCedars-Sinai Medical Center, Los Angeles, California; Cleveland Clinic Foundation, Cleveland, Ohio; University of Pennsylvania, Philadelphia, PennsylvaniaRecruitingAges 18 to 65Run by The Cleveland Clinic
New trials, status changes and new sites, straight from ClinicalTrials.gov. Unsubscribe anytime.
You'll get new recruiting trials, changes to trials, FDA decisions and condition news for Multiple Sclerosis. Turn any of these off from the link in every email.
Where Multiple Sclerosis trials are recruiting in the US
The US cities with the most Multiple Sclerosis trials recruiting are New York, New York (19), Chicago, Illinois (18), Boston, Massachusetts (13), St Louis, Missouri (13) and Cleveland, Ohio (12), counting trials with at least 1 open site in each city.
Hospitals that run trials for a rare condition often see more people with it than most clinics do, so this list can also help you find doctors who know Multiple Sclerosis, even if no trial fits you.
- Hunter College, Physical Therapy Department, City University of New York
- Mount Sinai Hospital
- TG Therapeutics Investigational Trial Site
- and 15 more
- Northwestern Memorial Hospital
- Shirley Ryan AbilityLab
- University of Illinois at Chicago
- and 5 more
- Brigham and Women's Hospital
- Brigham MS Center, 60 Fenwood Road
- Massachusetts General Hospital
- and 7 more
- Washington University School of Medicine
- Barnes Jewish Center for Clinical Imaging Research
- John L. Trotter Multiple Sclerosis Center, Washington University School of Medicine in St. Louis
- and 8 more
- Cleveland Clinic
- Cleveland Clinic Foundation
- Louis Stokes Cleveland VA Medical Center
- and 3 more
- National Institutes of Health Clinical Center
- Evidera
- Evidera INC.
- and 3 more
- Multiple Sclerosis Center at UW Medical Center - Northwest
- University of Washington
- Fred Hutchinson Cancer Center
- and 5 more
- Johns Hopkins University
- Baltimore Veterans Affairs Medical Center- Site Number : 8400163
- Johns Hopkins School of Medicine
- and 4 more
States with at least 1 open site: Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Virginia, Washington, West Virginia, Wisconsin.
Questions about finding a Multiple Sclerosis trial near you
Are there Multiple Sclerosis clinical trials near me?
As of October 12, 2026, 525 Multiple Sclerosis clinical trials are recruiting or about to open (368 recruiting now, 157 opening soon). 152 of them have at least 1 open site in the United States, across 41 states. Enter your ZIP code on this page to rank every one of them by the distance to its closest open site, with the sites shown on a map.
Which states have Multiple Sclerosis clinical trial sites?
As of October 12, 2026, recruiting Multiple Sclerosis trials list open sites in 41 states. The US cities with the most Multiple Sclerosis trials recruiting are New York, New York (19), Chicago, Illinois (18), Boston, Massachusetts (13), St Louis, Missouri (13) and Cleveland, Ohio (12), counting trials with at least 1 open site in each city.
What if there is no Multiple Sclerosis trial near me?
Some trials pay for or reimburse travel and lodging, and a few send staff or use local labs so fewer visits happen at the study site, so ask the study contact before ruling a trial out. You can also sign up on this page to get an email when a Multiple Sclerosis trial opens a new site or changes status.
How is the distance to a trial site measured?
Distances are straight-line miles from the center of your ZIP code to each study site's listed location, not driving distance. Your browser looks up the ZIP code's coordinates with a free map service, Zippopotam.us, and the ZIP code is never sent to or stored by Trial Friend.
FDA-approved for Multiple Sclerosis: Briumvi (ublituximab), Gilenya (fingolimod), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Zeposia (ozanimod), Ocrevus (ocrelizumab), Tysabri (natalizumab), Kesimpta (ofatumumab) and 2 more on the disease page.
Source: ClinicalTrials.gov, trials with status Recruiting or Not yet recruiting. Refreshed every 6 hours; counts as of October 12, 2026. Sites that ClinicalTrials.gov lists as closed or withdrawn are left out.